Selection of solid dosage form composition through drug-excipient compatibility testing.

A drug-excipient compatibility screening model was developed by which potential stability problems due to interactions of drug substances with excipients in solid dosage forms can be predicted. The model involved storing drug-excipient blends with 20% added water in closed glass vials at 50 degrees C and analyzing them after 1 and 3 weeks for chemical and physical stability. The total weight of drug-excipient blend in a vial was usually kept at about 200 mg. The amount of drug substance in a blend was determined on the basis of the expected drug-to-excipient ratio in the final formulation. Potential roles of several key factors, such as the chemical nature of the excipient, drug-to-excipient ratio, moisture, microenvironmental pH of the drug-excipient mixture, temperature, and light, on dosage form stability could be identified by using the model. Certain physical changes, such as polymorphic conversion or change from crystalline to amorphous form, that could occur in drug-excipient mixtures were also studied. Selection of dosage form composition by using this model at the outset of a drug development program would lead to reduction of "surprise" problems during long-term stability testing of drug products.

[1]  Kenneth R. Morris,et al.  Characterization of humidity-dependent changes in crystal properties of a new HMG-CoA reductase inhibitor in support of its dosage form development , 1994 .

[2]  N. K. Patel,et al.  The Effect of Selected Direct Compression Excipients on the Stability of Aspirin as a Model Hydrolyzable Drug , 1988 .

[3]  S. Varia,et al.  Photostabilization of uncoated tablets of sorivudine and nifedipine by incorporation of synthetic iron oxides , 1994 .

[4]  Bruno C. Hancock,et al.  Characteristics and significance of the amorphous state in pharmaceutical systems. , 1997, Journal of pharmaceutical sciences.

[5]  A. A. Dooren Design for Drug-Excipient Interaction Studies , 1983 .

[6]  Kenneth R. Morris,et al.  An integrated approach to the selection of optimal salt form for a new drug candidate , 1994 .

[7]  G Zografi,et al.  How does residual water affect the solid-state degradation of drugs in the amorphous state? , 1996, Journal of pharmaceutical sciences.

[8]  Donald C. Monkhouse,et al.  Whither Compatibility Testing , 1989 .

[9]  J. Valentine,et al.  EXTRAPOLATION OF APPEARANCE OF TABLETS AND POWDERS FROM ACCELERATED STORAGE TESTS. , 1964, Journal of pharmaceutical sciences.

[10]  S. Moreland,et al.  Synthesis and biological activity of novel calcium channel blockers: 2,5-dihydro-4-methyl-2-phenyl-1,5-benzothiazepine-3-carboxylic acid esters and 2,5-dihydro-4-methyl-2-phenyl-1,5-benzodiazepine-3-carboxylic acid esters. , 1987, Journal of medicinal chemistry.

[11]  V. Rudraraju,et al.  Approaches for improving the stability of ketorolac in powder blends. , 1995, Journal of pharmaceutical sciences.

[12]  J. T. Carstensen,et al.  Drug stability : principles and practices , 1995 .

[13]  J. Carstensen,et al.  EFFECT OF MOISTURE ON SOLID DOSAGE FORMS. CAN THE ARRHENIUS EQUATION BE USED AS A PREDICTOR , 1990 .

[14]  R. Johnson,et al.  Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine. , 1998, Journal of pharmaceutical sciences.